SUBSCRIBE: eNewsletter
Turkish researchers are reporting the results of small study that shows too much vitamin D may be associated with the severity of in disease ankylosing spondylitis patients. Learn more about this and other recent findings from spondylarthritis research in today's news roundup.
Updated treatment guidelines for hand, hip and knee osteoarthritis have been issued. In this slideshow, we highlight recommendations for the use (or not) of drug and nondrug treatments. These include strong recommendations for standard treatment options, such as weight loss and Tai Chi, and strong recommendations against treatments with pharmacologicals, such as glucosamine and chondroitin sulfate (except for hand osteoarthritis). Learn more in this slideshow.
In a review published last month in Autoimmunity Reviews, British researchers outline factors physicians should consider when contemplating tapering biologic therapies in patients with inflammatory arthritis. How best to wean patients from biologic therapy is an issue that comes up more frequently these days as patients increasingly achieve remission or low disease activity. In this slideshow, we highlight considerations physicians may want to consider in treating these patients.
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
In this slideshow, we revisit some of our most popular stories of the year: Insurers weigh in on step therapy, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis, conflicting studies were published on treatments that may (or, may not) cause deadly infections, among others.
Rheumatoid arthritis and type 2 diabetes mellitus share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes. In this slideshow, we highlight some of the similarities.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
Studies that explore the efficacy and safety of JAK inhibitors for rheumatoid arthritis are among those we selected as most noteworthy in 2019. Also, at the top of the list, a study that shows glucocorticoids, not necessarily biologics, raise the infection risk after joint replacement surgery. Learn more in this slideshow.
There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements.
In this slideshow, we review the year's most noteworthy new books in rheumatology as selected by BookAuthority.com. This is by no means a comprehensive list, but it offers a good look at the diverse selections of rheumatology books published this year.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
